Genmab A/S (CPH:GMAB)

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Denmark Revenue	-	3.33B	2.87B
Netherlands Revenue	-	1.00M	-
United States Revenue	-	180.00M	131.00M
Japan Revenue	-	213.00M	122.00M
Revenue (Total)	4.13B	3.72B	3.12B

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
DARZALEX Royalties Revenue	2.66B	2.44B	2.02B
Kesimpta Royalties Revenue	504.00M	443.00M	323.00M
TEPEZZA Royalties Revenue	117.00M	105.00M	106.00M
Other Product Royalties Revenue	150.00M	111.00M	69.00M
Total Royalties Revenue	3.43B	3.10B	2.52B
Net Product Sales	483.00M	398.00M	253.00M
Reimbursement Revenue	37.00M	53.00M	144.00M
Milestone Revenue	110.00M	97.00M	145.00M
Collaboration Revenue	69.00M	70.00M	62.00M
Revenue (Other)	-3.43B	-3.10B	-2.52B
Revenue (Total)	4.13B	3.72B	3.12B

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Net Product Sales	483.00M	398.00M	253.00M
J&J Revenue	2.80B	2.57B	2.09B
Roche Revenue	117.00M	106.00M	107.00M
Novartis Revenue	507.00M	446.00M	408.00M
BioNTech Revenue	14.00M	40.00M	127.00M
Pfizer Revenue	75.00M	77.00M	77.00M
AbbVie Revenue	-	66.00M	58.00M
Other Collaboration Partner Revenue	-	22.00M	-
Total Other Collaboration Partner Revenue	132.00M	88.00M	58.00M
Revenue (Total)	4.13B	3.72B	3.12B

Data Source: Fiscal.ai Last updated: Jun 30, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 22, 2026

Data Sources Report a data error